Nausea on a GLP-1: 44 percent on Wegovy and 29 percent on Zepbound
Nausea reached 44 percent on Wegovy 2.4 mg and 29 percent on Zepbound 10 mg in the clinical trials printed on their FDA labels, against 16 and 8 percent on placebo. GLP Chart read both labels on DailyMed, revised June and August 2026.
| Label and dose | Who was in the trial | On the drug | On placebo |
|---|---|---|---|
| Wegovy 2.4 mg (June 2026 label) | adults with obesity or overweight, n=2,116 | 44% | 16% (n=1,261) |
| Wegovy 2.4 mg (June 2026 label) | adults in the trial comparing the two maintenance doses, n=304 | 35% | 13% (n=303) |
| Wegovy 7.2 mg (June 2026 label) | adults in the trial comparing the two maintenance doses, n=1,311 | 39% | 13% (n=303) |
| Zepbound 5 mg (August 2026 label) | adults with obesity or overweight, n=630 | 25% | 8% (n=958) |
| Zepbound 10 mg (August 2026 label) | adults with obesity or overweight, n=948 | 29% | 8% (n=958) |
| Zepbound 15 mg (August 2026 label) | adults with obesity or overweight, n=941 | 28% | 8% (n=958) |
| Ozempic 0.5 mg (June 2026 label) | adults with type 2 diabetes, n=260 | 15.8% | 6.1% (n=262) |
| Ozempic 1 mg (June 2026 label) | adults with type 2 diabetes, n=261 | 20.3% | 6.1% (n=262) |
| Mounjaro 5 mg (August 2026 label) | adults with type 2 diabetes, n=237 | 12% | 4% (n=235) |
| Mounjaro 10 mg (August 2026 label) | adults with type 2 diabetes, n=240 | 15% | 4% (n=235) |
| Mounjaro 15 mg (August 2026 label) | adults with type 2 diabetes, n=241 | 18% | 4% (n=235) |
The dose moves it, but not in a straight line
On three of the four labels the rate climbs with the dose. Ozempic reads 15.8 percent at 0.5 mg and 20.3 percent at 1 mg. Mounjaro reads 12 percent at 5 mg and 18 percent at 15 mg. Wegovy's own high-dose table reads 35 percent at 2.4 mg and 39 percent at 7.2 mg.
Zepbound is the exception. Its table reads 25 percent at 5 mg, 29 percent at 10 mg and 28 percent at 15 mg, so the peak is the middle step rather than the top one. That matters if you are at 10 mg and being told the next step will be worse. On this label the 15 mg column is a point lower than the 10 mg one.
The two weight-management labels also sit far above the two diabetes labels for the same molecules. Wegovy is 44 percent and Ozempic tops out at 20.3 percent. The doses differ and so do the trial populations. Ozempic's table also cuts at 5 percent, so a lower rate never reaches it. Read each figure against its own placebo column rather than against the other drug.
What a slower ladder costs
Neither label says what the slower route costs. On some programs the lower dose is the cheaper one and on others the price does not move at all.
| Drug | Cheapest program we track | At the maintenance dose | At the top dose it publishes |
|---|---|---|---|
| Wegovy | Knownwell | $299 a month | Publishes one figure only |
| Zepbound | CVS MinuteClinic | $428 a month | $528 a month |
LifeMD charges $200 a month more at the top of its ladder than at the dose below it. Holding a step for 4 weeks on that plan saves $200. Ask the program what it charges at each dose before you agree to climb.
Compare every program at its real maintenance price →
What the labels actually tell a prescriber
Wegovy's label carries a tolerability sentence: If patients do not tolerate a dose during dosage escalation, consider delaying dosage escalation for 4 weeks.
Zepbound's carries a different one: If patients do not tolerate a maintenance dosage, consider a lower maintenance dosage.
The two diabetes labels carry neither. Ozempic and Mounjaro make every step past the first conditional on needing more glycemic control, and say nothing about pausing for side effects. If you are on a diabetes label, the dose conversation is a different one.
Frequently asked questions
How common is nausea on a GLP-1?
The FDA labels report it as the most common adverse reaction on both molecules. Wegovy's label puts nausea at 44 percent at 2.4 mg against 16 percent on placebo. Zepbound's puts it at 25 percent at 5 mg, 29 percent at 10 mg and 28 percent at 15 mg, against 8 percent on placebo.
Does a higher dose mean more nausea?
Mostly, and not evenly. Ozempic runs 15.8 percent at 0.5 mg and 20.3 percent at 1 mg. Mounjaro runs 12 percent at 5 mg and 18 percent at 15 mg. Wegovy's own high-dose table reads 35 percent at 2.4 mg and 39 percent at 7.2 mg. Zepbound is the exception: it peaks at 29 percent at 10 mg and reads 28 percent at 15 mg.
What does the label say to do about it?
Wegovy's label says that if a patient does not tolerate a dose during escalation, consider delaying escalation for 4 weeks. Zepbound's says that if a patient does not tolerate a maintenance dosage, consider a lower maintenance dosage. Both sentences are addressed to the prescriber.
Does holding at a lower dose cost less?
It depends on the program. Some publish one price at every dose and some charge more at each step up, so the same clinical decision saves money on one plan and nothing on another.
Is the nausea permanent?
The labels do not answer that. They report how many people in each trial arm had the reaction at any point, not how long it lasted. Anyone still unable to keep fluids down should call the prescriber the same day.
Every dosage sentence on this page is written to a prescriber, not to you. Holding a dose, dropping back or stopping changes what the drug is doing. Take the label language to the appointment.
Sources
Evidence checked August 31, 2026
Every figure above is taken from the document beside it, the FDA label or the trial that produced it, so you can read the source instead of trusting us. No clinician reviews these pages. What that means.
- The 44 percent Wegovy figure, the 35 against 39 percent comparison at 2.4 mg and 7.2 mg, and the tolerability sentence about delaying escalationFDA prescribing information for Wegovy, injection and tablets (DailyMed, revised June 2026)
- The Zepbound rates at 5 mg, 10 mg and 15 mg and the sentence about considering a lower maintenance dosageFDA prescribing information for Zepbound (DailyMed, revised August 2026)
- The Ozempic rates at 0.5 mg and 1 mg in adults with type 2 diabetesFDA prescribing information for Ozempic injection (DailyMed, revised June 2026)
- The Mounjaro rates at 5 mg, 10 mg and 15 mg in adults with type 2 diabetesFDA prescribing information for Mounjaro (DailyMed, revised August 2026)
